| Medical and Health Sciences | Lifetime | 508 | CA 27 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 616 | CA 21 | 99.87 |
| Nutrition and Dietetics | Lifetime | 33 | CA 5 | 99.79 |
| Medical Physiology | Lifetime | 100 | CA 4 | 99.84 |
| Cardiology and Cardiovascular Medicine | Lifetime | 187 | CA 12 | 99.77 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 357 | CA 8 | 98.93 |
| Immunology | Lifetime | 849 | CA 29 | 97.24 |
| Biochemistry | Lifetime | 444 | CA 13 | 93.61 |
| Nephrology | Lifetime | 893 | CA 38 | 84.55 |
| Medical Biochemistry | Lifetime | 665 | CA 22 | 70.11 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 187 | CA 10 | 98.88 |
| Nutrition and Dietetics | 2021-2025 | 118 | CA 4 | 96.67 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 457 | CA 17 | 86.57 |
| Infectious Diseases | 2021-2025 | 871 | CA 29 | 76.54 |
| Immunology | 2021-2025 | 970 | CA 21 | 56.88 |
| Nitric Oxide and Endothelin Effects | Lifetime | 5 | CA 1 | 99.93 |
| Hormonal Regulation and Hypertension | Lifetime | 11 | CA 2 | 99.83 |
| Magnesium in Health and Disease | Lifetime | 1 | CA 1 | 99.77 |
| Renin-Angiotensin System Studies | Lifetime | 3 | CA 1 | 99.86 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | Lifetime | 3 | CA 1 | 99.77 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 10 | CA 2 | 99.76 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 27 | CA 2 | 99.70 |
| Sodium Intake and Health | Lifetime | 11 | CA 1 | 99.68 |
| Blood Pressure and Hypertension Studies | Lifetime | 76 | CA 3 | 99.65 |
| Receptor Mechanisms and Signaling | Lifetime | 323 | CA 16 | 99.10 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 55 | CA 5 | 98.55 |
| Cardiovascular Disease and Adiposity | Lifetime | 246 | CA 9 | 98.64 |
| Redox biology and oxidative stress | Lifetime | 69 | CA 1 | 98.18 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 243 | CA 10 | 98.20 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 363 | CA 13 | 97.51 |
| Cardiovascular Health and Disease Prevention | Lifetime | 589 | CA 17 | 97.43 |
| Angiogenesis and VEGF in Cancer | Lifetime | 529 | CA 14 | 96.87 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 405 | CA 14 | 96.82 |
| Apelin-related biomedical research | Lifetime | 168 | CA 6 | 95.17 |
| Antioxidant Activity and Oxidative Stress | Lifetime | 922 | CA 28 | 95.26 |
| Ion Transport and Channel Regulation | Lifetime | 967 | CA 38 | 93.28 |
| Biomarkers in Disease Mechanisms | Lifetime | 428 | CA 14 | 88.15 |
| Cerebrovascular and genetic disorders | Lifetime | 896 | CA 23 | 76.16 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 48 | CA 2 | 98.92 |
| Magnesium in Health and Disease | 2021-2025 | 4 | CA 1 | 98.26 |
| Sodium Intake and Health | 2021-2025 | 18 | CA 1 | 97.58 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 27 | CA 1 | 93.51 |
| Hormonal Regulation and Hypertension | 2021-2025 | 148 | CA 5 | 94.60 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 94 | CA 8 | 93.21 |
| Cardiac, Anesthesia and Surgical Outcomes | 2021-2025 | 890 | CA 71 | 93.28 |
| Cancer Treatment and Pharmacology | 2021-2025 | 863 | CA 21 | 85.00 |
| Ion Channels and Receptors | 2021-2025 | 162 | CA 4 | 83.02 |
| Nitric Oxide and Endothelin Effects | 2021-2025 | 175 | CA 1 | 81.26 |
| Renin-Angiotensin System Studies | 2021-2025 | 89 | CA 5 | 82.63 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 724 | CA 22 | 72.08 |
| Cerebrovascular and genetic disorders | 2021-2025 | 291 | CA 7 | 62.47 |
| Apelin-related biomedical research | 2021-2025 | 453 | CA 23 | 52.28 |
| Redox biology and oxidative stress | 2021-2025 | 593 | CA 12 | 43.75 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 907 | CA 6 | 34.52 |
